ENTL Entelos Regs

    


Entelos Inc.



Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive
computer models of human physiology and "virtual patients" for drug discovery
and development, announced today that Pfizer, Inc. ("Pfizer", NYSE:PFE) has
signed an agreement with Entelos to expand and continue research using the
Entelos(R) Cardiovascular PhysioLab(R) platform. The expanded research will
focus on identifying biomarkers and interpretation of clinical study data.
Financial terms are not disclosed.

The Entelos Cardiovascular PhysioLab platform is an innovative and predictive
computer model that simulates patients and drug effects, and represents key
biological mechanisms and disease processes that can help to explain the
underlying causes of heart attacks, strokes, and other serious cardiovascular
conditions in multiple patient types.

The platform mathematically represents the relative contribution of circulating
lipids, systemic inflammation and local vessel inflammation to the progression
of atherosclerosis, a key driver leading to heart disease. Simulations test the
effects of specific therapies on "virtual patients" by computing changes in
plaque geometry and composition that can then be used to predict the long-term
risk of a major cardiovascular event for each patient type. The predictive
capabilities of the platform have been rigorously validated by demonstrating
consistency with a wide range of published clinical trial results.

Entelos has supported a variety of preclinical and clinical research in prior
work conducted with Pfizer over multiple stages.

"We believe that our cardiovascular disease platform can help Pfizer gain even
greater value from the tremendous amount of information available in their
historical clinical trial databases," commented James Karis, president and CEO
of Entelos. "Rather than just 'data mining', our powerful, engineering-based,
dynamic simulation models of human physiology can do a much better job of
identifying which patients would benefit most from a specific treatment. More
importantly, we can often explain why certain patients respond better than
others, enabling not only better patient care, but helping to keep effective
drugs on the market that are safe for a targeted subpopulation. We look forward
to continuing our work with Pfizer and to conducting research on their highest
priority projects in cardiovascular disease, cholesterol regulation, and
atherosclerosis."

For further information please contact:

Entelos, Inc.
James Karis, President and CEO                Tel: +1 650 572 5400
Jill Fujisaki, VP Investor Relations

Evolution Securities
Bobbie Hilliam, Associate Director            Tel +44 (0) 20 7071 4300

Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson             Tel +44 (0) 20 7466 5000

Notes for Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver injury.
Entelos offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys.

About Entelos(R) Cardiovascular PhysioLab(R) Platform

Entelos(R) Cardiovascular PhysioLab(R) platform is a large-scale mathematical
model of human physiology that supports research in the area of cardiovascular
disease. The platform includes the physiology and pathophysiology of cholesterol
metabolism, atherosclerosis, and plaque rupture, and has been developed to
support drug discovery research, biomarker identification, and clinical
development of cholesterol-lowering and anti-inflammatory therapies that could
treat and ultimately prevent atherosclerotic plaque formation. The platform can
be thought of as a dynamic "flight simulator" that enables rapid testing in
silico (i.e. in a computer) to see the effects of multiple interacting factors,
particularly lipid levels and inflammatory processes, and their contribution to
the risk of cardiovascular events.

The Cardiovascular PhysioLab platform includes four submodels:

    --  Cholesterol metabolism - includes both "good" and "bad" cholesterol,
        high density lipoprotein (HDL) and low density lipoprotein (LDL),
        respectively. Represents the dynamic regulation of lipoprotein particle
        size, number, and composition, all of which have a significant impact on
        disease progression and prognosis, as well as their altered synthesis
        and uptake by the liver.

    --  Atherogenesis - represents the mechanisms of lipid retention,
        modification, uptake, and processing by vascular and inflammatory cells,
        the regulation of which leads to plaque development and progression.

    --  Plaque stability - integrates changes in plaque composition, size, and
        geometry by calculating peak stresses in the plaque wall that can lead
        to unstable plaque and rupture.

    --  Cardiovascular risk - employs statistical methods and longitudinal
        patient data to translate the plaque stability readouts into the
        likelihood of cardiovascular risk.

Risk factors (e.g., smoking, diabetes, and hypertension) and known or
hypothesized genetic variants are represented across the physiologic submodels
of the platform. In this manner, a broad range of "virtual patients" can be
generated in the platform, tested against existing clinical data, and then used
for simulations of novel therapies and clinical protocols.

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024